Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Fineline Cube Mar 25, 2026
Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Fineline Cube Mar 25, 2026
Company Deals

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 24, 2026
Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026
Company Deals

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Fineline Cube Mar 24, 2026
Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Fineline Cube Mar 25, 2026
Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Fineline Cube Mar 25, 2026
Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Fineline Cube Mar 25, 2026
Company Drug

Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC

Fineline Cube Apr 3, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results...

Company Deals

Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation

Fineline Cube Apr 3, 2023

The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...

Company Drug

Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis

Fineline Cube Apr 3, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...

Company Drug

Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012

Fineline Cube Apr 3, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...

Company

Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization

Fineline Cube Apr 3, 2023

China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...

Company

Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates

Fineline Cube Mar 31, 2023

China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...

Company Deals Digital

ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector

Fineline Cube Mar 31, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has...

Company Deals

Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility

Fineline Cube Mar 31, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...

Company Drug

HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC

Fineline Cube Mar 31, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...

Company Deals

Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’

Fineline Cube Mar 31, 2023

Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...

Company Drug

Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Mar 31, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership

Fineline Cube Mar 31, 2023

Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...

Company Drug

Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...

Company Deals

Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration

Fineline Cube Mar 31, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment

Fineline Cube Mar 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...

Medical Device

IceCure Medical Gains NMPA Approval for Cryoablation Technology in China

Fineline Cube Mar 31, 2023

Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...

Company Deals

SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal

Fineline Cube Mar 31, 2023

China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...

Company Deals

Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade

Fineline Cube Mar 30, 2023

QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi...

Company Drug

ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development

Fineline Cube Mar 30, 2023

China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...

Posts pagination

1 … 517 518 519 … 640

Recent updates

  • Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance
  • Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer
  • China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026
  • Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication
  • Clover Bio Reports Positive SCB‑1019 Phase I Data – RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Company Drug

Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.